CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Nigella sativa seeddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00327054
NCT00327054Phase 2Completed

Effectiveness of Nigella Sativa (Kalonji) Seed in Dyslipidemia: A Randomized Controlled Trial

Aga Khan University·interventional·Posted May 17, 2006·Updated Jul 1, 2015

In Brief

A Phase 2 clinical trial evaluating Nigella sativa seed for Hypercholesterolemia and 3 related conditions. Completed, enrolled 80 participants across 1 site.

Detailed Summary

This is a pilot study. The aim of the investigators' study is to evaluate the effectiveness of nigella sativa seed in the treatment of dyslipidemia. Dyslipidemia is a common risk factor for cardiovascular disease, the leading cause for morbidity and mortality among patients. Nigella sativa is an easily available and acceptable remedy to treat dyslipidemia and at a low cost. It is expected that by scientifically determining the effectiveness of this intervention it will lead to its widespread use. This will provide a low cost alternative to treat dyslipidemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPakistan
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 17, 2006
Enrollment StartFeb 1, 2006
Study CompletionMar 1, 2007
TodayJul 2, 2026
Posted 20.1 years ago

Interventions

Nigella sativa seeddrug